Aker BioMarine

Equities

AKBM

NO0010886625

Fishing & Farming

Real-time Oslo Bors 05:08:03 2024-04-19 am EDT 5-day change 1st Jan Change
68.1 NOK -1.30% Intraday chart for Aker BioMarine -0.58% +48.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aker BioMarine AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aker BioMarine AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Aker BioMarine AS, Q4 2023 Earnings Call, Feb 14, 2024
Aker BioMarine ASA Receives Purchase Order for Algae-Based Omega-3 Oils CI
Aker BioMarine Wins $6 Million Order for Omega-3 Oils; Production Capacity Expansion Planned MT
Aker BioMarine AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Aker BioMarine AS, Q3 2023 Earnings Call, Nov 01, 2023
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal MT
Aker Biomarine Begins Krill Oil Sales in South Korea MT
Aker Biomarine Announces Successful Launch of Superba Krill Oil in South Korea CI
Aker BioMarine's Krill Oil Brand Wins Australian Nod for Two Health Claims MT
Aker BioMarine Gains Regulatory Approval for US Commercial Launch of Dietary Supplement MT
Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US CI
Aker BioMarine AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Aker BioMarine AS, Q2 2023 Earnings Call, Jul 14, 2023
Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023 CI
Aker BioMarine AS Announces Intention to Change Group Financial Reporting and Legal Entity Structure CI
Aker BioMarine Spinoff, Microsoft Norway Team Up on Plastic Circularity MT
Aker BioMarine AS Provides Sales Guidance for the Second Quarter of 2023 CI
Transcript : Aker BioMarine AS, Q1 2023 Earnings Call, Apr 28, 2023
Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aker BioMarine AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Aker BioMarine AS Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil CI
Aker BioMarine AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart Aker BioMarine
More charts
Aker Biomarine ASA is a Norway-based biotech innovator and Antarctic krill-harvesting company. It consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine's focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.261 USD
Average target price
5.763 USD
Spread / Average Target
-7.95%
Consensus
  1. Stock Market
  2. Equities
  3. AKBM Stock
  4. News Aker BioMarine
  5. Aker BioMarine : Unveils Novel Protein INVI